Targeting growth factors in lung cancer

Print
Published on Friday, 31 March 2017

Abstract

Lung cancer causes more deaths than any other malignancy in the developed world.

Advances in surgical techniques and chemotherapy/radiotherapy regimes have produced only minimal improvements in long-term survival.

New therapeutic interventions are urgently required.

Research has indicated that growth factor signaling may be an important novel target in lung cancer therapy.

Preclinical studies have demonstrated the role of extracellular growth factors in lung cancer cell proliferation, metastasis, and resistance to cytotoxic therapy, and have elucidated the key molecular components of growth factor-signaling cascades.

This has enabled the development of selective growth factor inhibitors, which have been evaluated in clinical trials and are now an accepted component of advanced lung cancer treatment.

Further research is underway to improve the efficacy of this growth factor-targeted therapy.

This article will outline the important aspects of this translational research indicating the growth factor-signaling pathways identified in lung cancer, clinical trials of anti-growth factor therapy, and potential future research directions.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences and "Some additional publications about hGH/GH-GHRH/GHRF/GRF" section;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Pleural Mesothelioma: clinical records on 11 patients treated with Di Bella's Method;

- Malignant pleural mesothelioma, stage T3-T4. Consideration of a case study;

- Excellent result in a Mesothelioma case treated exclusively with Di Bella Method for over 4 years and still treatment with positive results;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.